AUTOLUS THERAPEUTICS PLC

Autolus Therapeutics prepares to unveil Q2 2026 results, offering insights into its cutting‑edge T‑cell cancer therapies and market outlook.

Autolus Therapeutics PLC reports early success in lupus and pediatric B‑ALL trials, fresh board appointment and promising data at ASH 2025—could boost investor confidence and pipeline expansion.

Autolus Therapeutics PLC’s Q2 2025 earnings report reveals a mixed bag, with strong product revenue offset by significant operational losses, leaving investors uncertain about the company’s long-term viability.

Autolus Therapeutics PLC has reported promising long-term results from its FELIX study, demonstrating the potential of its Obe-Cel cell therapy to induce durable remission in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Autolus Therapeutics PLC reported a promising start to 2025, with its flagship product AUCATZYL generating $9.0 million in net product revenue and receiving conditional marketing authorization in the UK.